New York, NY -- (SBWIRE) -- 01/03/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), Baltic Trading Ltd (NYSE:BALT), Horizon Pharma Inc (NASDAQ:HZNP), Mast Therapeutics Inc (NYSEMKT:MSTX)
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) showed a volume of 1.56 million shares by the end of last trade whereas the average volume of the stock remained 2.68 million shares. The stock opened the session at $1.40 but then moved to $1.44. At that price, the stock showed a positive performance of 4.35%. Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. The Company’s pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. The development priorities in oncology are the completion of Phase 3 trials with perifosine in colorectal cancer (CRC) and in multiple myeloma (MM),
Will AEZS Continue To Move Higher? Find Out Here
Baltic Trading Ltd (NYSE:BALT) opened the session at $6.28 and closed the session at $6.44. Traded with volume of 1.55 million shares in the prior session and the average volume of the stock remained 1.07 million shares. Baltic Trading Limited conducts shipping business focused on the drybulk industry spot market. The Company was formed by Genco Shipping & Trading Limited (Genco), an international drybulk shipping company. The Company’s fleet consists of two Capesize vessels, four Supramax vessels and three Handysize vessels with an aggregate carrying capacity of approximately 672,000 deadweight tons. Its fleet contains three groups of sister ships,
Is BALT a Solid Investment at These Levels? Read This Report For Details
Horizon Pharma Inc (NASDAQ:HZNP) opened the session at $7.80 and closed the session at $7.61. The stock showed a negative performance of -0.13% in previous trading session. Traded with volume of 1.55 million shares in the prior session and the average volume of the stock remained 2.01 million shares. Horizon Pharma, Inc. operates as a biopharmaceutical company. It is focused on developing and commercializing medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases.
Why Should Investors Buy HZNP After the Recent Fall? Just Go Here and Find Out
Mast Therapeutics Inc (NYSEMKT:MSTX) the stock advanced 2.18% and finished the session at $0.472. Traded with volume of 1.54 million shares in the prior session and the average volume of the stock remained 1.01 million shares. The beta of the stock remained 1.07. Mast Therapeutics, Inc., formerly ADVENTRX Pharmaceuticals, Inc., is a development-stage company biopharmaceutical company focused on developing product candidates. The Company's product candidate is ANX-188, a rheologic, antithrombotic and cytoprotective agent that improves microvascular blood flow and has application in treating a range of diseases and conditions, such as complications arising from sickle cell disease.
Will MSTX Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)